Influence of monomethylfumarate on monocytic cytokine formation - Explanation for adverse and therapeutic effects in psoriasis?

Archives of Dermatological Research

Volumn 289, Issue 11, 1997, Pages 623-630

  Asadullah, Khusru ^a   Schmid, Holger ^a   Friedrich, Markus ^a   Randow, Felix ^a   Volk, Hans Dieter ^a   Sterry, Wolfram ^a   Döcke, Wolf Dietrich ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cytokine formation; IL 10; Monocytes; Monomethylfumarate; Psoriasis; TNF alpha

Indexed keywords

CYTOKINE; ENDOTOXIN; FUMADERM; FUMARIC ACID; FUMARIC ACID DIMETHYL ESTER; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CULTURE; CELL SECRETION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; MACROPHAGE; MONOCYTE; MONONUCLEAR CELL; ORAL DRUG ADMINISTRATION; PATIENT MONITORING; PRIORITY JOURNAL; PSORIASIS; SIDE EFFECT; T LYMPHOCYTE ACTIVATION;

EID: 0030828067     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004030050251     Document Type: Article

References (50)

1. Altmeyer P, Nüchel C (1996) Systemtherapie der Psoriasis. Dtsch Med Wovhrnschr 121:1605-1607
2. Altmeyer PJ, Matthes U, Pawlak F, Hoffmann K, Frosch PJ, Ruppert P, Wassilew SW, Horn T, Kreysel HW, Lutz G, Barth J, Rietzschel I, Joshi RK (1994) Anti-psoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 30:977-981
3. Asadullah K, Woiciechowsky C, Döcke WD, Egerer K, Kox WJ, Vogel S, Sterry W, Volk HD (1995) Very low monocytic HLA-DR expression indicates high risk of infection - immunomonitoring for patients after neurosurgery and patients during high dose steroid therapy. Eur J Emerg Med 2:184-190
4. Asadullah K, Woiciechowsky C, Döcke WD, Liebenthal C, Wauer H, Kox W, Volk HD, Vogel S, von Baehr R (1995) Immunodepression following neurosurgical procedures. Crit Care Med 23:1976-1983
5. Asadullah K, Döcke WD, Haeufller A, Sterry W, Volk HD (1996) Progression of mycosis fungoides is associated with increasing cutaneous expression of IL-10 mRNA. J Invest Dermatol 107:833-837
6. Asadullah K, Friedrich M, Döcke WD, Jahn S, Volk HD, Sterry W (1997) Enhanced expression of T-cell activation and natural killer cell antigens indicates systemic anti-tumor response in early primary cutaneous T-cell lymphoma (CTCL). J Invest Dermatol 108:743-747
7. Baker BS, Fry L (1992) The immunology of psoriasis. Br J Dermatol 126:1-9
8. Bayard W, Hunziker T, Krebs A, Speiser P, Joshi R (1987) Perorale Langzeitbehandlung der Psoriasis mit Fumarsäurederivaten. Hautarzt 38:279-285
9. Cavaillon JM (1995) The nonspecific nature of endotoxin tolerance. Trends Microbiol 3:320-324
10. D'Andrea A, Aste-Amezega M, Valiante NM, Ma X, Kubin M, Trinchieri G (1993) Interleukin 10 (IL-10) inhibits human lymphocyte interferon-γ production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 178:1041-1048
11. De Jong R, Bezemer AC, Zomerdijk TP, van de Pouw-Kraan T, Ottenhoff TH, Nibbering PH (1996) Selective stimulation of T helper 2 cytokine responses by anti-psoriasis agent monomethylfumarate. Eur J Immunol 26:2067-2074
12. De Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE (1991) Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 174:1209-1220
13. Döcke WD, Syrbe U, Meinecke A, Platzer C, Makki A, Asadullah K, Klug C, Zuckermann H, Reinke P, Brunner H, von Baehr R, Volk HD (1994) Improvement of monocyte function - a new therapeutic approach? In: Reinhart K, Eyrich K, Sprung C (eds) Sepsis - current perspectives in pathophysiology and therapy. Springer, Berlin Heidelberg New York, pp 473-500
14. Döcke WD, Eberhardt B, Höflich C, Volk HD (1997) Catecholamines induce rapid release and enhanced production of interleukin(IL)-10 by monocytes. Crit Care Med 25:A67
15. Döcke WD, Lenz A, Sabat R, Randow F, Volk HD (1997) Differential effects of sepsis mediators on in vitro type 1/type 2 cytokine production: prevention and reversal of type 2 switch by anti-IL-10 and IL-12, respectively (abstract). Crit Care Med 25:A114
16. Döcke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, Kox W (1997) Monocyte deactivation in septic patients: restitution by IFN-γ treatment. Nat Med 3:678-681
17. Enk CD, Sredni D, Blauvelt A, Katz SI (1995) Induction of IL-10 gene expression in human keratinocytes by UVB exposure in vivo and vitro. J Immunol 154:4851-4856
18. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A (1991) IL-10 inhibits cytokine production by activated macrophages. J Immunol 147:3815-3822
19. Guillou PJ (1993) Biological variation in the development of sepsis after surgery or trauma. Lancet 342:217-220
20. Jeffes EW 3rd, Lee GC, Said S, Sabahi M, McCullough JL, Herrod R, Alzona CP, Linden KG, Soundararajan D, Edwards S, Weinstein GD (1995) Elevated numbers of proliferating mononuclear cells in the peripheral blood of psoriatic patients correlate with disease severity. J Invest Dermatol 105:733-738
21. Jenkins JK, Malyak M, Arend WP (1994) The effects of interleukin-10 on interleukin-1 receptor antagonist and interleukin-1 beta production in human monocytes and neutrophils. Lymphokine Cytokine Res 13:47-54
22. Kägi MK, Wthrich B, Montano E, Barandun J, Blaser K, Walker C (1994) Differential cytokine profiles in peripheral blood lymphocyte supernatants and skin biopsies from patients with different forms of atopic dermatitis, psoriasis and normal individuals. Int Arch Allergy Immunol 103:332-340
23. Kern F, Ode-Hakim S, Nugel H, Volk HD, Reinke P (1996) CD3+/LFA-I "bright" T cells represent memory-type effector cells, which during immune activation in kidney graft recipients are marked by increased cytokine mRNA levels. Transplant Proc 27:896-899
24. Kristensen M, Deleuran B, Eedy DJ, Feldmann M, Breathnach SM, Brennan FM (1992) Distribution of interleukin 1 receptor agonist protein (IRAP), interleukin 1 receptor, and interleukin 1 alpha in normal and psoriatic skin. Decreased expression of IRAP in psoriatic lesional epidermis. Br J Dermatol 127:305-311
25. Matthes U, Hartwig R, Altmeyer P (1995) Der antipsoriatische Effekt der Fumarsäurederivate. Akt Dermatol 21:40-44
26. Mitra RS, Judge TA, Nestle FO, Turka LA, Nickoloff BJ (1995) Psoriatic skin-derived dendritic cell function is inhibited by exogenous IL-10. Differential modulation of B7-1 (CD80) and B7-2 (CD86) expression. J Immunol 154:2668-2677
27. Neuner P, Urbanski A, Trautinger F, Müller A. Kirnbauer R, Kapp A, Schöpf E, Schwarz T, Luger TA (1991) Increased IL-6 production by monocytes and keratinocytes in patients with psoriasis. J Invest Dermatol 97:27-33
28. Nibbering PH, Thio B,. Zomerdijk TP, Bezemer AC, Beijersbergen RL, van Furth R (1993) Effects of monomethylfumarate on human granulocytes. J Invest Dermatol 101:37-42
29. Nickoloff BJ (1991) The cytokine network in psoriasis. Arch Dermatol 127:871-884
30. Nickoloff BJ, Turka LA (1994) Immunological function of non-professional antigen-presenting cells: new insights from studies of T-cell interactions with keratinocytes. Immunol Today 15:464-469
31. Nieboer C, de Hoop D, Langendijk PN, van Loenen AC, Gubbels J (1990) Fumaric acid therapy in psoriasis: a double-blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester. Dermatologica 181:33-37
32. Nugteren-Huying WM, van der Schroeff JG, Hermans J, Suurmond D (1990) Fumaric acid therapy for psoriasis: a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 22:311-312
33. Ockenfels HM, Kleber G, Funk R, Goos M (1997) The fumaric acid therapy of psoriasis: cytokine modulation in psoriatic co-cultures (abstract). Br J Dermatol 135:835
34. Pigatto PD, Pigatto LB, Bigardi A, Altomare G, Finzi AF (1990) Factors secreted by untreated psoriatic monocytes enhance neutrophil function. J Invest Dermatol 94:372-376
35. Platzer C, Ode Hakim S, Reinke P, Döcke WD, Ewert R, Volk HD (1994) Quantitative PCR analysis of cytokine transcription patterns in peripheral mononuclear cells after anti-CD3 rejection therapy using two novel multispecific competitor fragments. Transplantation 58:264-268
36. Platzer C, Meisel Ch, Vogt K, Platzer M, Volk HD (1995) Up-regulation of monocytic IL-10 by tumor necrosis factor-alpha and c-AMP elevating drugs. Int Immunol 4:517-523
37. Randow F, Syrbe LJ, Meisel C, Krausch D, Zuckermann H, Platzer C, Volk HD (1995) Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor beta. J Exp Med 181:1887-1892
38. Sanchez-Cantu L, Rode HN, Christou NV (1989) Endotoxin tolerance is associated with reduced secretion of tumor necrosis factor. Arch Surg 124:1432-1435
39. Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, Meyer zum Büschenfelde KH, Fleischer B (1994) T cells involved in psoriasis vulgaris belong to the Th 1 subset. J Invest Dermatol 102:145-149
40. Sebök B, Bonnekoh B, Geisel J, Mahrle G (1994) Antiproliferative and cytotoxic profiles of antipsoriatic fumaric acid derivatives in keratinocyte cultures. Eur J Pharmacol 270:79-87
41. Sebök B, Bonnekoh B, Geisel J, Mahrle G (1994) IL-1 alpha-induced expression of ICAM-1 on cultured hyperproliferative keratinocytes: suppression by antipsoriatic dimethyl-fumarate. Int J Dermatol 33:367-370
42. Siegling A, Lehmann M, Platzer C, Emmrich F, Volk HD (1994) A novel multispecific competitor fragment for quantitative PCR analysis of cytokine gene expression in rats. J Immunol Methods 177:23-28
43. Teranishi Y, Mizutani H, Murata M, Shimizu M, Matsushima K (1995) Increased spontaneous production of IL-8 in peripheral blood monocytes from the psoriatic patient: Relation to focal infection and response to treatments. J Dermatol Sci 10:8-15
44. Thio HB, van der Schroeff JG, Nugteren-Huying WM, Vermeer BJ (1995) Long-term systemic therapy with dimethylfumarate and monoethylfumarate (Fumaderm®) in psoriasis. Journal of the European Academy of Dermatology and Venerology 4:35-40
45. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ (1993) The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 101:701-705
46. Valdimarsson H, Baker BS, Johnsdottir I, Fry L (1986) Psoriasis: a disease of abnormal keratinocyte proliferation induced by T lymphocytes. Immunol Today 7:256-259
47. Van Dijk E (1985) Fumarzuur voor de behandeling van patienten met psoriasis. Ned Tijdschr Geneeskd 129:485-486
48. Volk HD, Reinke P, Krausch D, Zuckermann H, Asadullah K, Müller JM, Kox WJ, Döcke WD (1996) Monocyte deactivation - rationale for a new therapeutic strategy in sepsis. Intensive Care Med 22:S474-481
49. Vollmer S, Menssen A, Trommler P, Schendel D, Prinz JC (1994) T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper type 1 and T helper type 2 cells. Eur J Immunol 24:2377-2382
50. Zheng M, Christophers E, Mrowietz U (1996) Decreased chemotactic activity and increased activation of T-lymphocytes in psoriasis and atopic dermatitis (abstract). J Invest Dermatol 106:924